Latest News

 

Beximco Pharmaceuticals Limited ("Beximco Pharma", "BPL" or "the Company"; AIM Symbol: BXP), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, today announces that the Company has won the award for the ’Best Company in an Emerging Market’ at the Scrip Awards, presented in London, England, on 29 November 2017. Rabbur Reza, Chief Operating Officer of Beximco Pharma, accepted the award on behalf of the Company.

Remains Bangladesh’s only pharmaceutical company to export pharmaceutical products to the US

Beximco Pharmaceuticals Limited ("BPL", "Beximco Pharma" or "Company"; AIM Symbol: BXP), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, today announces it has commenced the export of Sotalol Hydrochloride (80 mg, 120 mg and 160 mg), a generic version of the cardiovascular drug Betapace, to the US. Following the successful launch of Carvedilol to the US in August 2016, this is the second product from Beximco Pharma to be exported to the US.

Beximco Pharmaceuticals Limited ("Beximco Pharma", "BPL" or "the Company"; AIM Symbol: BXP), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, today announces its audited results for the 12 month period ended 30 June 2017.

Beximco Pharmaceuticals Limited ("BPL", "Beximco Pharma" or "Company"; AIM Symbol: BXP), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, today announces that it has entered into a non-binding Memorandum of Understanding (“MoU”) under which Beximco Pharma may acquire a majority shareholding (85.22%) in Nuvista Pharma Limited, a leading pharma company in Bangladesh specialising in hormones and steroid drugs (the “Proposed Acquisition”).

Beximco Pharmaceuticals Limited ("BPL", "Beximco Pharma" or "Company"; AIM Symbol: BXP), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, today announces it has commenced the export of Olopatadine, an ophthalmic product for treating the symptoms of eye allergy, to Canada.

Beximco Pharmaceuticals Limited ("Beximco Pharma" or "the Company"; AIM Symbol: BXP), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, announces the creation of a joint venture ("JV") with BioCare Manufacturing (M) Sdn Bhd ("BioCare") based in Malaysia, as the Company's first overseas manufacturing collaboration.

Beximco Pharmaceuticals Limited (“Beximco Pharma” or “the Company”; AIM Symbol: BXP), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, announces the creation of a joint venture (“JV”) with BioCare Manufacturing (M) Sdn Bhd (“BioCare”) based in Malaysia, as the Company’s first overseas manufacturing collaboration.

Beximco Pharma has received approval for its Metformin Hydrochloride extended-release tablets, 500 mg and 750 mg, from the U.S. Food and Drug Administration (US FDA) on 13th December 2016. These are generic equivalent of Bristol-Myers Squibb′s Glucophage XR tablets, 500 mg and 750 mg.

Sandoz and Beximco Pharmaceuticals Join the Medicines Patent Pool’s Growing Network of Generic Manufacturing Partners

Beximco Pharmaceuticals Limited ("BPL" or "the Company"; AIM Symbol: BXP), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, has received US Food and Drug Administration (FDA) approval for Sotalol Hydrochloride, a generic version of the cardiovascular drug Betapace, following submission of an Abbreviated New Drug Application (ANDA) in June 2014.